Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathieu Bosset

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
International Journal of Radiation Oncology, Biology, Physics|May 2, 2006
Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network studyMarco Krengli, Laura Masini, Johannes H A M Kaanders, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 21, 2007
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology GroupPhilip Poortmans, Alberto Bossi, Katia Vandeputte, et al.
International Journal of Radiation Oncology, Biology, Physics|November 29, 2024
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABRJuliette Thariat, Mathieu Bosset, Antoine Falcoz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2022
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02)Séverine Racadot, Isabelle Thennevet, Yaelle Ouldbey, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
International Journal of Radiation Oncology, Biology, Physics|May 2, 2006
Radiotherapy in the treatment of mucosal melanoma of the upper aerodigestive tract: analysis of 74 cases. A Rare Cancer Network studyMarco Krengli, Laura Masini, Johannes H A M Kaanders, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 21, 2007
Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology GroupPhilip Poortmans, Alberto Bossi, Katia Vandeputte, et al.
International Journal of Radiation Oncology, Biology, Physics|November 29, 2024
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABRJuliette Thariat, Mathieu Bosset, Antoine Falcoz, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2022
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02)Séverine Racadot, Isabelle Thennevet, Yaelle Ouldbey, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
Pageof 2